<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813786</url>
  </required_header>
  <id_info>
    <org_study_id>CYN12-PICO-CAPHST-07</org_study_id>
    <nct_id>NCT01813786</nct_id>
  </id_info>
  <brief_title>Clinical and Histological Evaluation of the 755nm Alexandrite Laser With Handpiece for the Treatment of Scars</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare efficacy and safety of handpieces on the 755nm Alexandrite laser for the treatment of
      scars.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject Biopsy Sampling</measure>
    <time_frame>3 months post last treatment</time_frame>
    <description>Histological examination of tissue samples will be compared between baseline and 3 months post treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Photographic evaluation as a measure of improvement.</measure>
    <time_frame>up to 3 months post last treatment</time_frame>
    <description>2D photographs to be taken at each visit and assessed at the end of the study by 2-3 blinded assessors for improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Biopsy Sampling</measure>
    <time_frame>2 weeks post treatment</time_frame>
    <description>Histological examination of tissue samples will be compared between baseline and 2 weeks post treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Biopsy Sampling</measure>
    <time_frame>1 month post treatment</time_frame>
    <description>Histological examination of tissue samples will be compared between baseline and 1 month post treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>up to 3 months post last treatment</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Scars</condition>
  <arm_group>
    <arm_group_label>755nm Alexandrite Laser with Handpiece 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Focusing energy on skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>755nm Alexandrite Laser with handpiece 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Focusing energy on skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>755nm Alexandrite laser with handpiece 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Focusing energy on skin</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>755nm Alexandrite Laser with handpiece 2</intervention_name>
    <description>Focusing energy on skin</description>
    <arm_group_label>755nm Alexandrite Laser with Handpiece 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>755nm Alexandrite Laser with handpiece 1</intervention_name>
    <description>focusing energy at skin surface</description>
    <arm_group_label>755nm Alexandrite laser with handpiece 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>755nm Alexandrite Laser with handpiece 3</intervention_name>
    <description>Focusing energy on skin</description>
    <arm_group_label>755nm Alexandrite Laser with handpiece 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is a healthy male or female between 18 and 85 years old

          2. Has unwanted scars not including atrophic scars and wishes to undergo laser
             treatments.

          3. Is willing to consent to participate in the study.

          4. Is willing to comply with all requirements of the study including biopsies, being
             photographed, following post treatment care and attending all treatment and follow up
             visits.

          5. Has Fitzpatrick skin types I to IV.

        Exclusion Criteria:

          1. The subject is female and pregnant, has been pregnant within the last 3 months, is
             currently breast feeding or planning a pregnancy during the study period.

          2. The subject is hypersensitive to light exposure OR takes photo sensitized medication.

          3. The subject has active or localized systemic infections.

          4. The subject has a coagulation disorder or is currently using anti-coagulation
             medication (including but not limited to heavy aspirin therapy {greater than 81 mg per
             day}).

          5. The subject has any condition which, in the investigator's opinion, would make it
             unsafe for the subject to participate in this research study.

          6. The subject is currently enrolled in an investigational drug or device trial, or has
             received an investigational drug or been treated with an investigational device within
             3 months prior to entering this study.

          7. The subject has used Accutane within 6 months prior to enrollment.

          8. The subject has the need to be exposed to artificial tanning devices or excessive
             sunlight during the trial.

          9. The subject has had prior treatment with parenteral gold therapy (gold sodium
             thiomalate).

         10. The subject has a history of keloids.

         11. The subject has evidence of compromised wound healing.

         12. The subject has a history of squamous cell carcinoma or melanoma.

         13. The subject has a history of immunosuppression/immune deficiency disorders (including
             HIV infection or AIDS) or use of immunosuppressive medications.

         14. The subjects has an allergy to lidocaine and epinephrine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Krantz</last_name>
    <role>Study Director</role>
    <affiliation>Cynosure, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2013</study_first_submitted>
  <study_first_submitted_qc>March 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <last_update_submitted>February 7, 2014</last_update_submitted>
  <last_update_submitted_qc>February 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

